GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Life Sciences

More

  • Results with Alnylam Pharmaceuticals and Medicines Co's experimental product ALN-PCSsc highlight the competition for a market tipped to generate billions of dollars in sales. Amgen's Repatha and a rival product, Praluent, from Sanofi and Regeneron Pharmaceuticals, are each expected to generate more than $2 billion a year in sales by 2020, according to...

  • Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...

  • The universe is dying—but you shouldn't panic yet Saturday, 15 Aug 2015 | 12:00 PM ET
    Big Bang Theory

    A new study confirmed something researchers have suspected for decades: The stars that populate our universe are burning themselves out.

  • *Mallinckrodt shares up flat in early trading. Aug 10- Dublin- based drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings. Mallinckrodt's purchase of Therakos from investment firm The Gores Group comes...

  • Aug 10- Drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc from investment firm The Gores Group in a deal valued at about $1.33 billion to strengthen its presence in hospitals. Therakos is a maker of immune cell therapy, which is delivered through extracorporeal photopheresis- a form of therapy used to treat patients with skin...

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • Data from Thomson Reuters published on Tuesday showed the number of innovative medicines, or new molecular entities, launched globally in 2014 hit a 17- year high of 46, up from 29 in 2013.. Phase III terminations totalled 56 in the last three years, down from 68 in 2009-2011, according to the Thomson Reuters 2015 CMR Pharmaceutical R&D Factbook.

  • *Worldwide cancer drug spending $100 billion in 2014. LONDON, Aug 3- New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. Pricey immunotherapies, offering long-lasting responses, are already starting to change...

  • LONDON, July 31- Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea. In the event, it proved about as safe as a flu vaccine, said University of Reading virologist Ben Neuman, but it was still not given to children or...

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • How effective is new malaria vaccine? Friday, 24 Jul 2015 | 11:40 AM ET
    How effective is new malaria vaccine?

    Suki Virji, analyst for Scrip Intelligence, discusses the malaria vaccine developed by GlaxoSmithKline, which has received a "green light" by the European Medicines Agency.

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...

  • July 23- Switzerland's Roche is lining up more new drugs to drive sales in a two-year window before cheap copycats of its biotech medicines hit the market, including a promising cancer immunotherapy it hopes to launch by late 2016.. The shares rose 1.1 percent by 0920 GMT on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive."

  • July 23- Switzerland's Roche expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio of new and established medicines. The shares rose 1.5 percent in early trading on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive." Its three top-selling cancer...

  • BRIEF-NOVAVAX INC SAYS POSITIVE TOP-LINE DATA FROM PHASE 1. *Positive top-line data from phase 1 trial of ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with matrix-m. *Trial demonstrated that ebola GP vaccine was highly immunogenic, well-tolerated and resulted in significant antigen dose-sparing.

  • July 21- Amgen Inc's cholesterol fighting drug was approved by the European Commission, giving the keenly anticipated treatment a head start over a rival drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA. Amgen did not immediately reveal when the drug would be available or its pricing strategy. Amgen's drug is designed for biweekly doses of...

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • UPDATE 1-Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:41 PM ET

    July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential blockbuster drug in late stage development for inflammatory bowel disease and multiple sclerosis. The move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to...